InSilico Medicine Cayman TopCo (INSILICO) released its Monthly Return for Equity Issuer for the period ended 31 March 2026, confirming stable share capital metrics and continued compliance with Hong Kong Stock Exchange (HKEX) listing rules.
Key Takeaways
• Authorised Share Capital – Ordinary shares authorised remained at 1.27 billion, each with a par value of USD 0.0000005, keeping total authorised capital unchanged at USD 635.
• Issued Share Capital and Treasury Shares – Issued shares held steady at 572.40 million, with no treasury shares on the balance sheet. – No new shares were issued, cancelled, or repurchased during the month.
• Public Float – Management confirmed compliance with the minimum 15 % public-float requirement stipulated under Main Board Rule 13.32B.
• Equity Incentive Schemes – Pre-IPO share options outstanding fell by 2.46 million to 27.96 million due to lapses; no options were exercised, and therefore no funds were raised. – Post-IPO share option scheme (approved 15 December 2025) has no options outstanding but allows for up to 27.87 million shares to be issued upon future grants. – Restricted Share Units (RSUs) that could be issued under pre-IPO plans total 2.25 million. The post-IPO RSU scheme was also approved on 15 December 2025 but recorded no issuances.
• Other Securities – The company reported no warrants, convertible securities, or other arrangements affecting share capital during the reporting period.
INSILICO’s unchanged capital structure and confirmation of public-float sufficiency signal stable shareholding dynamics ahead of future corporate actions.
Comments